Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
OHE Occasional Paper Critiques the Claxton et al. £13,000 per QALY Estimate
24 February 2015
OHE has published an Occasional Paper highlighting the significant shortage of data that forced Claxton et al. to rely on a large number of strong assumptions…
Spotlight on OHE: Opportunity Costs of NICE Decisions in Wales and HESG 2015
20 January 2015
Jon Sussex presents on the opportunity costs of implementing NICE decisions in Wales, and OHE attend HESG in Leeds, January 2015.
Cost-per-QALY in the US and Britain: Damned if You Do and Damned if You Don’t
1 December 2015
Professor Weinstein presents a comprehensive analysis of the differences in attitudes between the US and the UK around how cost-effectiveness analysis (CEA) fits into the health…
Model of Behaviour within Fuzzy Budget Constraints
1 December 2015
This paper presents a model to capture the behaviour of health sector decision makers when making resource allocation decisions on the level and mix of healthcare…
Data Governance Arrangements for Real-World Evidence
1 November 2015
The objective of this OHE Consulting Report was to understand and develop a view on the core principles that should govern how Real-World Data (RWD) is…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
1 October 2015
Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. As value is likely to differ across major indications, if…
International Comparison of Medicines Usage: Quantitative Analysis from a Swedish Perspective
1 May 2015
The OHE undertook an analysis of the uptake of medicines in 13 high income countries. The UK perspective on this was published in November 2014 by…
A Framework for Payer Assessment of the Value of New Technologies: A US Approach
1 March 2015
Dr Steven Pearson has convened a US policy workgroup of payers, drug and device manufacturers, patients’ groups, and clinician specialty societies to help develop a “value…
Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
1 March 2015
A new OHE Consulting Report considers the data capabilities in the UK for monitoring medicine use according to indication using real world data. A new OHE…